Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls

Photo of Lee Jackson
By Lee Jackson Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls

© ipopba / Getty Images

The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narrative on inflation is portrayed. In addition, another huge question investors have is when the tapering of the $120 billion per month quantitative easing purchases will begin. Some feel that could begin as early as the end of the summer.

24/7 Wall St. is reviewing some big analyst calls seen on Tuesday. We have included the latest analyst call on each stock, as well as a recent trading history and the consensus targets among analysts.

In case you missed it, Monday’s early analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Sarepta Therapeutics and Spirit Airlines.

Alliance Data Systems Corp. (NYSE: ADS): RBC Capital Markets resumed coverage on the stock with an Outperform rating and a $126 price target. The stock has traded in a 52-week range of $38.88 to $128.16 and has a Wall Street consensus price target of $133.43.

[nativounit]

CBRE Group Inc. (NYSE: CBRE): Wolfe Research started coverage on the real estate giant with an Outperform rating and a $112 price target. Over the past year, the shares have traded between $41.03 and $90.21. The consensus price objective is $93.20.

Cimarex Energy Inc. (NYSE: XEC): UBS downgraded the energy leader to Neutral from Buy and also lowered the price target to $83 from $91. The shares have traded between $23.39 and $74.92 over the past 52 weeks and have a consensus price target of $83.12.

ITT Inc. (NYSE: ITT | ITT Price Prediction): Citigroup started coverage with a Buy rating and a $113 price target. The 52-week trading range is $53.65 to $101.32, and the consensus price target is posted at $107.91.

Myriad Genetics Inc. (NASDAQ: MYGN): Raymond James started coverage with a Market Perform rating. The shares have traded in a 52-week range of $10.54 to $33.97 and have a $26.63 consensus price target.

Nestle S.A. (NSRGY): Exane BNP Paribas raised the chocolate giant to Neutral from Underperform. The over-the-counter-traded stock has a 52-week range of $104.50 to $128.17 and a consensus price objective of $136.50.

Principal Financial Group Inc. (NYSE: PFG): Piper Sandler downgraded the insurance and investment giant to Neutral from Overweight and lowered the firm’s price objective to $70 from $72. That compares with a consensus target of $67. Over the past 52 weeks, the shares have traded between $37.02 and $67.97 a share.

UniQure N.V. (NASDAQ: QURE): BTIG Research initiated coverage with a Buy rating and a $46 price target. The stock has traded in a 52-week range of $28.58 to $71.45 and has a consensus price target of $68.53.

[recirclink id=895980]
Stifel feels that the software group will see above-average growth in coming years, driven by secular demand that shows no signs of abating. The firm’s four sizzling stock picks offer the best entry points this year and could be big alpha producers for the rest of 2021.

See how Warren Buffett’s first-quarter stock picks are faring. Also, check out why Goldman Sachs has downgraded Kinder Morgan and Ferrari.
[wallst_email_signup]

Photo of Lee Jackson
About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618